NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02409342,A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110],https://clinicaltrials.gov/study/NCT02409342,,COMPLETED,"This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.",YES,"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","DRUG: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Pemetrexed","Overall Survival (OS) in the TC3 or IC3-WT Populations, OS is defined as the time from randomization to death from any cause., From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)|Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, OS is defined as the time from randomization to death from any cause., From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)","Progression-free Survival (PFS) in the TC3 or IC3-WT Populations, PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested., From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested., From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)|Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations, Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1., Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months)|Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1., Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months)|Duration of Response (DOR) in the TC3 or IC3-WT Populations, DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first., From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first., From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)|Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations, Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations, Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, Baseline to 1 year or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)|Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations, Baseline to 2 years or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)|Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations, TTD in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant., Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)|Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations, Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant., Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)|TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations, TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \[multi-item scale\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis., Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)|OS in Participants With PD-L1 Expression, OS is defined as the time from randomization to death from any cause., From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)|Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1, Investigator-assessed PFS according to RECIST v1.1 in the PD-L1 (defined with SP263 IHC assay), From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|OS in Participants With Blood Tumor Mutational Burden (bTMB), OS is defined as the time from randomization to death from any cause., From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)|Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1, PFS according to RECIST v1.1 in the bTMB subpopulations., From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)|Minimum Observed Serum Concentration (Cmin) of Atezolizumab, Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days)|Maximum Observed Serum Concentration (Cmax) of Atezolizumab, 0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)|Percentage of Participants With at Least One Adverse Event, Percentage of participants with at least one adverse event., Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)|Percentage of Participants With Anti-therapeutic Antibodies (ATAs), Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,572,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GO29431|2014-003083-21,2015-07-20,2020-02-04,2022-03-08,2015-04-06,2021-02-18,2023-03-15,"University of California San Diego, La Jolla, California, 92093, United States|Yale Cancer Center, New Haven, Connecticut, 06520, United States|Lynn Cancer Institute - West, Boca Raton, Florida, 33428, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|Oregon Health & Science Uni, Portland, Oregon, 97239, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, 38138, United States|Vanderbilt University Medical Center; Multiple Sclerosis Center, Nashville, Tennessee, 37204, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, 22408, United States|VA Puget Sound Health Care Sys, Seattle, Washington, 98108, United States|Oncovida*X, Salvador, BA, 41820-021, Brazil|Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, 29308-014, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, 20560-120, Brazil|Associacao Hospital de Caridade Ijui*X; Departamento De Oncologia, Ijui, RS, 98700-000, Brazil|Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia, Passo Fundo, RS, 99010-260, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, 90020-090, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Instituto Joinvilense de Hematologia E Oncologia, Joinville, SC, 89201-260, Brazil|*X*Fundacao PIO XII, Barretos, SP, 14784-400, Brazil|Hospital Santa Marcelina, Sao Paulo, SP, 08270-070, Brazil|Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira, São Paulo, SP, 01246 000, Brazil|Harbin Medical University Tumor Hospital, Harbin City, 150081, China|CHU Angers, Angers, 49933, France|Hospital d Instructions des Armees Percy, Clamart, 92141, France|Hôpital Universitaire Dupuytren, Limoges, 87042, France|Clinique Clémentville, Montpellier, 34070, France|Centre D'oncologie de Gentilly, Nancy, 54100, France|Hopital Tenon, Paris, 75020, France|Centre Hospitalier Regional La Reunion Site Felix Guyon, Saint Denis Cedex, 97405, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, 94160, France|Centre Hospitalier Regional Sud Reunion, Saint-pierre, 97448, France|Centre Paul Strauss, Strasbourg, 67000, France|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, 82131, Germany|Pius-Hospital Oldenburg, Oldenburg, 26121, Germany|Sotiria Chest Hospital of Athens, Athens, 11527, Greece|IASO General Hospital of Athens, Athens, 155 62, Greece|Metropolitan Hospital, Athens, 185 47, Greece|Attikon University General Hospital, Chaidari, 124 62, Greece|University General Hospital of Larissa, Larissa, 412 21, Greece|University General Hospital of Patras, Patras, 265 00, Greece|Thermi Clinic, Thermi, Thessaloniki, 57001, Greece|Bioclinic Thessaloniki, Thessaloniki, 546 22, Greece|EUROMEDICA General Clinic of Thessaloniki; Gastroenterology Department, Thessaloniki, 54645, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, 564 29, Greece|Georgios Papanikolaou General Hosp. of Thessaloniki, Thessaloniki, 57010, Greece|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, 4400, Hungary|Pecsi Tudomanyegyetem, Pecs, 7624, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, 5004, Hungary|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|Centro Di Riferimento Oncologico; Struttura Operativa Complessa Di Oncologia Medica B, Aviano, Friuli-Venezia Giulia, 33081, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, 24100, Italy|Azienda Ospedaliera Istituti Ospitalieri, Cremona, Lombardia, 26100, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, 20132, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy|Azienda Socio Sanitaria Territoriale ? ASST di Monza, Monza, Lombardia, 20052, Italy|Istituto Nazionale dei Tumori, Monza, Lombardia, 20052, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, 20089, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|Azienda Ospedaliero-Universitaria ?PoliclinicoVittorio Emanuele?- P.O. G. Rodolico; Oncologia Medica, Catania, Sicilia, 95123, Italy|Azienda Ospedaliera Universitaria Integrata Verona; UOC Oncologia, Verona, Veneto, 37126, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, 464-8681, Japan|Nagoya University Hospital; Respiratory Medicine, Aichi, 466-8560, Japan|Kyushu University Hospital; Respiratory, Fukuoka, 812-8582, Japan|Hokkaido University Hospital, Hokkaido, 060-8648, Japan|Kobe City Medical Center General Hospital; Respiratory Medicine, Hyogo, 650-0047, Japan|Hyogo Cancer Center; Thoracic Oncology, Hyogo, 673-8558, Japan|Ibaraki Prefectural Central Hospital; Division of respiratory, Ibaraki, 309-1793, Japan|Sendai Kousei Hospital; Pulmonary Medicine, Miyagi, 980-0873, Japan|Okayama University Hospital; Respiratory and Allergy Medicine, Okayama, 700-8558, Japan|Osaka International Cancer Institute; Thoracic Oncology, Osaka, 541-8567, Japan|Kansai Medical university Hospital; Thoracic Oncology, Osaka, 573-1191, Japan|Osaka Habikino Medical Center, Osaka, 583-8588, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, 591-8555, Japan|Saitama Cancer Center; Thoracic Oncology, Satima, 362-0806, Japan|National Cancer Center Hospital; Thoracic Medical Oncology, Tokyo, 104-0045, Japan|Tokyo Medical University Hospital; Dept of Surgery, Tokyo, 160-0023, Japan|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, 03181, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie; Oddzial onkologii z pododdzialem chemioterapii, Olsztyn, 10-357, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, 05-400, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, 60-569, Poland|Med-Polonia Sp. z o.o., Poznan, 60-693, Poland|Teo Health SA - Saint Constantin Hospital, Brasov, 500091, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, 400015, Romania|Oncology Center Sf. Nectarie, Craiova, 200347, Romania|Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, 700483, Romania|Sibiu Emergency Clinical County Hospital, Sibiu, 550245, Romania|Oncocenter Clinical Oncology, Timi?oara, 300210, Romania|Oncomed SRL, Timisoara, 300239, Romania|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, 163045, Russian Federation|Federal State Institution Medical Radiology Research Center, Obninsk, Kaluga, 249036, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, 105229, Russian Federation|Saint Petersburg Clinical Hospital of the Russian Academy of Sciences, St. Petersburg, Sankt Petersburg, 194017, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Tatarstan, 420029, Russian Federation|Regional Clinical Oncology Center, Ryazan, 390046, Russian Federation|Mordovia State University, Saransk, 430032, Russian Federation|Leningrad Regional Clinical Hospital, St Petersburg, 194291, Russian Federation|St. Petersburg Med Univ; n.a. I.P. Pavlov; Pulmonology Research, St Petersburg, 197089, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, 400138, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Institute of Lung Diseases Vojvodina, Sremska Kamenica, 21204, Serbia|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, 08916, Spain|Consorcio Hospitalario Provincial de Castellon, Castellon DE LA Plana/castello DE LA Plana, Castellon, 12002, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, 07010, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, 07198, Spain|Hospital Universitario A Coruña, Coruna, LA Coruña, 15006, Spain|Hospital Universitario Cruces, Barakaldo, Vizcaya, 48903, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, 08035, Spain|Complejo Hospitalario de Jaen, Jaen, 23007, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, 50009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Prince of Songkla University; Department Of Internal Medicine, Faculty Of Medicine, Hat Yai, 90110, Thailand|Khon Kaen University, Khon Kaen, 40002, Thailand|Chiang Rai Prachanukroh Hospital, Muang, 57000, Thailand|Buddhachinnaraj Hospital, Phitsanulok, 65000, Thailand|Cukurova University Medical Faculty Balcali Hospital, Adana, 1330, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, 06100, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, 34000, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, 35100, Turkey|Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi, Izmir, 35110, Turkey|Inonu University Faculty of Medicine Turgut Ozal Medical Center, Malatya, 44280, Turkey|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, 61070, Ukraine|Municipal Noncomercial Enterprise Odessa Regional Oncology Center ofthe Odessa StateAdministration, Odesa, Kherson Governorate, 65055, Ukraine|Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Disp, Sumy, Kholm Governorate, 40005, Ukraine|Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council - PPDS; Chemotherapy, Dnipro, KIEV Governorate, 49102, Ukraine|Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway, Kyiv, KIEV Governorate, 02096, Ukraine|Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council, Vinnytsia, KIEV Governorate, 21029, Ukraine|The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council, Lutsk, Volhynian Governorate, 43018, Ukraine|Private Enterprise Private Manufacturing Company Acinus, Kirovograd, 25006, Ukraine|Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom|Colchester General Hospital, Colchester, Essex, CO4 5JL, United Kingdom|Christie Hospital, Manchester, M20 3BG, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/42/NCT02409342/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/42/NCT02409342/SAP_001.pdf"
